Clinical Microbiology and Antimicrobial Chemotherapy. 2013; 15(1):35-46
According to international post-marketing trials, levofloxacin now belongs to the antimicrobial agents being in a great demand in clinical practice. One of the main indications for its use is community-acquired pneumonia (CAP). This review article is dedicated to 20-year on-market experience of levofloxacin and provides data on clinical efficacy of levofloxacin in the treatment of CAP, pharmacokinetics, pharmacodynamics, and safety. Despite the 20-year clinical experience, levofloxacin remains one of the most successful antimicrobials for the treatment of CAP, and it is reflected in current international guidelines presented in this review.